KWM
RPRX icon

Kingsview Wealth Management’s Royalty Pharma RPRX Stock Holding History

Kingsview Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Buy
+6,377
New +$332K ﹤0.01% 1111
2024
Q3 		– Sell
-67,145
Closed -$1.77M – 1147
2024
Q2 		$1.77M Buy
+67,145
New +$1.86M 0.04% 381
2024
Q1 		– Sell
-45,573
Closed -$1.28M – 1059
2023
Q4 		$1.28M Buy
+45,573
New +$1.25M 0.04% 395

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingsview Wealth Management's RPRX Position: Q2 2026 in Review

Kingsview Wealth Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 6,377 shares worth $358K. The stake represents ﹤0.01% of the portfolio and ranks #1111 among its holdings. This is a return to the name: Kingsview Wealth Management previously reported a position in RPRX as recently as Q2 2024.

Kingsview Wealth Management first reported a position in RPRX in Q4 2023 and has held it in 3 quarters since. The position peaked at $1.77M in Q2 2024. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Kingsview Wealth Management held 6,377 shares of Royalty Pharma worth $358K as of Q2 2026.
  • Royalty Pharma was a new Kingsview Wealth Management position in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1111 holding.
  • Kingsview Wealth Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 3 quarters since.
  • Kingsview Wealth Management's Royalty Pharma position peaked at $1.77M in Q2 2024.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.